Cargando…
Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure
Frailty is a common comorbidity associated with adverse events in patients with heart failure, and early recognition is key to improving its management. We hypothesized that the AST to ALT ratio (AAR) could be a marker of frailty in patients with heart failure. Data from the FRAGILE-HF study were an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184951/ https://www.ncbi.nlm.nih.gov/pubmed/34099767 http://dx.doi.org/10.1038/s41598-021-91368-z |
_version_ | 1783704682777018368 |
---|---|
author | Maeda, Daichi Kagiyama, Nobuyuki Jujo, Kentaro Saito, Kazuya Kamiya, Kentaro Saito, Hiroshi Ogasahara, Yuki Maekawa, Emi Konishi, Masaaki Kitai, Takeshi Iwata, Kentaro Wada, Hiroshi Hiki, Masaru Dotare, Taishi Sunayama, Tsutomu Kasai, Takatoshi Nagamatsu, Hirofumi Ozawa, Tetsuya Izawa, Katsuya Yamamoto, Shuhei Aizawa, Naoki Yonezawa, Ryusuke Oka, Kazuhiro Momomura, Shin-ichi Matsue, Yuya |
author_facet | Maeda, Daichi Kagiyama, Nobuyuki Jujo, Kentaro Saito, Kazuya Kamiya, Kentaro Saito, Hiroshi Ogasahara, Yuki Maekawa, Emi Konishi, Masaaki Kitai, Takeshi Iwata, Kentaro Wada, Hiroshi Hiki, Masaru Dotare, Taishi Sunayama, Tsutomu Kasai, Takatoshi Nagamatsu, Hirofumi Ozawa, Tetsuya Izawa, Katsuya Yamamoto, Shuhei Aizawa, Naoki Yonezawa, Ryusuke Oka, Kazuhiro Momomura, Shin-ichi Matsue, Yuya |
author_sort | Maeda, Daichi |
collection | PubMed |
description | Frailty is a common comorbidity associated with adverse events in patients with heart failure, and early recognition is key to improving its management. We hypothesized that the AST to ALT ratio (AAR) could be a marker of frailty in patients with heart failure. Data from the FRAGILE-HF study were analyzed. A total of 1327 patients aged ≥ 65 years hospitalized with heart failure were categorized into three groups based on their AAR at discharge: low AAR (AAR < 1.16, n = 434); middle AAR (1.16 ≤ AAR < 1.70, n = 487); high AAR (AAR ≥ 1.70, n = 406). The primary endpoint was one-year mortality. The association between AAR and physical function was also assessed. High AAR was associated with lower short physical performance battery and shorter 6-min walk distance, and these associations were independent of age and sex. Logistic regression analysis revealed that high AAR was an independent marker of physical frailty after adjustment for age, sex and body mass index. During follow-up, all-cause death occurred in 161 patients. After adjusting for confounding factors, high AAR was associated with all-cause death (low AAR vs. high AAR, hazard ratio: 1.57, 95% confidence interval, 1.02–2.42; P = 0.040). In conclusion, AAR is a marker of frailty and prognostic for all-cause mortality in older patients with heart failure. |
format | Online Article Text |
id | pubmed-8184951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81849512021-06-08 Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure Maeda, Daichi Kagiyama, Nobuyuki Jujo, Kentaro Saito, Kazuya Kamiya, Kentaro Saito, Hiroshi Ogasahara, Yuki Maekawa, Emi Konishi, Masaaki Kitai, Takeshi Iwata, Kentaro Wada, Hiroshi Hiki, Masaru Dotare, Taishi Sunayama, Tsutomu Kasai, Takatoshi Nagamatsu, Hirofumi Ozawa, Tetsuya Izawa, Katsuya Yamamoto, Shuhei Aizawa, Naoki Yonezawa, Ryusuke Oka, Kazuhiro Momomura, Shin-ichi Matsue, Yuya Sci Rep Article Frailty is a common comorbidity associated with adverse events in patients with heart failure, and early recognition is key to improving its management. We hypothesized that the AST to ALT ratio (AAR) could be a marker of frailty in patients with heart failure. Data from the FRAGILE-HF study were analyzed. A total of 1327 patients aged ≥ 65 years hospitalized with heart failure were categorized into three groups based on their AAR at discharge: low AAR (AAR < 1.16, n = 434); middle AAR (1.16 ≤ AAR < 1.70, n = 487); high AAR (AAR ≥ 1.70, n = 406). The primary endpoint was one-year mortality. The association between AAR and physical function was also assessed. High AAR was associated with lower short physical performance battery and shorter 6-min walk distance, and these associations were independent of age and sex. Logistic regression analysis revealed that high AAR was an independent marker of physical frailty after adjustment for age, sex and body mass index. During follow-up, all-cause death occurred in 161 patients. After adjusting for confounding factors, high AAR was associated with all-cause death (low AAR vs. high AAR, hazard ratio: 1.57, 95% confidence interval, 1.02–2.42; P = 0.040). In conclusion, AAR is a marker of frailty and prognostic for all-cause mortality in older patients with heart failure. Nature Publishing Group UK 2021-06-07 /pmc/articles/PMC8184951/ /pubmed/34099767 http://dx.doi.org/10.1038/s41598-021-91368-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Maeda, Daichi Kagiyama, Nobuyuki Jujo, Kentaro Saito, Kazuya Kamiya, Kentaro Saito, Hiroshi Ogasahara, Yuki Maekawa, Emi Konishi, Masaaki Kitai, Takeshi Iwata, Kentaro Wada, Hiroshi Hiki, Masaru Dotare, Taishi Sunayama, Tsutomu Kasai, Takatoshi Nagamatsu, Hirofumi Ozawa, Tetsuya Izawa, Katsuya Yamamoto, Shuhei Aizawa, Naoki Yonezawa, Ryusuke Oka, Kazuhiro Momomura, Shin-ichi Matsue, Yuya Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
title | Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
title_full | Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
title_fullStr | Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
title_full_unstemmed | Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
title_short | Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
title_sort | aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184951/ https://www.ncbi.nlm.nih.gov/pubmed/34099767 http://dx.doi.org/10.1038/s41598-021-91368-z |
work_keys_str_mv | AT maedadaichi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT kagiyamanobuyuki aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT jujokentaro aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT saitokazuya aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT kamiyakentaro aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT saitohiroshi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT ogasaharayuki aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT maekawaemi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT konishimasaaki aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT kitaitakeshi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT iwatakentaro aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT wadahiroshi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT hikimasaru aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT dotaretaishi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT sunayamatsutomu aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT kasaitakatoshi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT nagamatsuhirofumi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT ozawatetsuya aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT izawakatsuya aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT yamamotoshuhei aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT aizawanaoki aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT yonezawaryusuke aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT okakazuhiro aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT momomurashinichi aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure AT matsueyuya aspartateaminotransferasetoalanineaminotransferaseratioisassociatedwithfrailtyandmortalityinolderpatientswithheartfailure |